|
1
|
Lesokhin AM, Ansell SM, Armand P, Scott
EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ,
Lebovic D, et al: Nivolumab in patients with relapsed or refractory
hematologic malignancy: Preliminary results of a phase Ib study. J
Clin Oncol. 34:2698–2704. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kirkegaard MM, Coupland SE, Prause JU and
Heegaard S: Malignant lymphoma of the conjunctiva. Surv Ophthalmol.
60:444–458. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Armitage JO, Gascoyne RD, Lunning MA and
Cavalli F: Non-Hodgkin lymphoma. Lancet. 390:298–310. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kochenderfer JN, Dudley ME, Kassim SH,
Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ,
Hughes MS, Sherry RM, et al: Chemotherapy-refractory diffuse large
B-cell lymphoma and indolent B-cell malignancies can be effectively
treated with autologous T cells expressing an anti-CD19 chimeric
antigen receptor. J Clin Oncol. 33:540–549. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wilson WH, Young RM, Schmitz R, Yang Y,
Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano
J, et al: Targeting B cell receptor signaling with ibrutinib in
diffuse large B cell lymphoma. Nat Med. 21:922–926. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tilly H, Gomes da Silva M, Vitolo U, Jack
A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW,
Pfreundschuh M, et al: ESMO Guidelines Committee: Diffuse large
B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 26 Suppl
5:v116–v125. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scott DW, Mottok A, Ennishi D, Wright GW,
Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta
P, et al: Prognostic significance of diffuse large B-cell lymphoma
cell of origin determined by digital gene expression in
formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol.
33:2848–2856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sehn LH and Gascoyne RD: Diffuse large
B-cell lymphoma: Optimizing outcome in the context of clinical and
biologic heterogeneity. Blood. 125:22–32. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choi J, Goh G, Walradt T, Hong BS, Bunick
CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, et al: Genomic
landscape of cutaneous T cell lymphoma. Nat Genet. 47:1011–1019.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Birge RB, Boeltz S, Kumar S, Carlson J,
Wanderley J, Calianese D, Barcinski M, Brekken RA, Huang X,
Hutchins JT, et al: Phosphatidylserine is a global
immunosuppressive signal in efferocytosis, infectious disease, and
cancer. Cell Death Differ. 23:962–978. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McDermott DF, Sosman JA, Sznol M, Massard
C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fassò M, Wang YV,
et al: Atezolizumab, an anti-programmed death-ligand 1 antibody, in
metastatic renal cell carcinoma: Long-term safety, clinical
activity, and immune correlates from a phase Ia study. J Clin
Oncol. 34:833–842. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon
YK and Chung DH: Programmed death-1 ligand 1 and 2 are highly
expressed in pleomorphic carcinomas of the lung: Comparison of
sarcomatous and carcinomatous areas. Eur J Cancer. 51:2698–2707.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cedrés S, Ponce-Aix S, Zugazagoitia J,
Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A,
Martinez P and Felip E: Analysis of expression of programmed cell
death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
PLoS One. 10:e01210712015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pregno P, Chiappella A, Bellò M, Botto B,
Ferrero S, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga
M, et al: Interim 18-FDG-PET/CT failed to predict the outcome in
diffuse large B-cell lymphoma patients treated at the diagnosis
with rituximab-CHOP. Blood. 119:2066–2073. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schumacher TN and Schreiber RD:
Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Patel SP and Kurzrock R: PD-L1 Expression
as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther.
14:847–856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ohaegbulam KC, Assal A, Lazar-Molnar E,
Yao Y and Zang X: Human cancer immunotherapy with antibodies to the
PD-1 and PD-L1 pathway. Trends Mol Med. 21:24–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kranz LM, Diken M, Haas H, Kreiter S,
Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, et al:
Systemic RNA delivery to dendritic cells exploits antiviral defence
for cancer immunotherapy. Nature. 534:396–401. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Howitt BE, Shukla SA, Sholl LM,
Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC,
D'Andrea AD, Wu CJ, et al: Association of polymerase e-mutated and
microsatellite-instable endometrial cancers with neoantigen load,
number of tumor-infiltrating lymphocytes, and expression of PD-1
and PD-L1. JAMA Oncol. 1:1319–1323. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Muro K, Chung HC, Shankaran V, Geva R,
Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al:
Pembrolizumab for patients with PD-L1-positive advanced gastric
cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial.
Lancet Oncol. 17:717–726. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
